Emtricitabine/tenofovir disoproxil fumarate vs Etravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Emtricitabine/tenofovir disoproxil fumarate · Truvada
Marketed by Gilead Sciences
NCT00323544 · Phase 3 · completed
This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07584122 (registry estimate)
Reported efficacy
The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)
Result source: NCT00323544
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
Reported efficacy
Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)
Result source: NCT00254046
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Emtricitabine/tenofovir disoproxil fumarate | Etravirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757805 other results
| 56% vs 39%a+17 vs placeboNCT00254046 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00323544 | —Not posted · NCT00255099 |
| CD4 count, change (week 48) | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578012 other results
| —Not posted · NCT00255099 |
HIV-1 RNA below 50 copies/mL (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
5 other results
- 85.2% vs 87.4% NCT01108510
- 73.1% vs 66% NCT02275780
- 72.1% vs 74.1% NCT01108510
- 77.9% vs 79.3% NCT01108510
- 71.6% vs 79.7% NCT01108510
- Etravirine
- 56% vs 39%a+17 vs placeboNCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- —Not posted · NCT00323544
- Etravirine
- —Not posted · NCT00255099
CD4 count, change (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
12 other results
- 192.7 vs 185.6 NCT02275780
- 310 vs 332 NCT01108510
- 277 vs 287 NCT01108510
- 291 vs 256 NCT00089505
- 223 vs 256 NCT00089505
- 213 vs 219 NCT01108510
- 172 vs 172 NCT00089505
- 350 vs 343 NCT01108510
- 191 vs 172 NCT00089505
- 158 vs 146 NCT01380080
- 96 vs 102 NCT01380080
- 8 vs 34 NCT00724711
- Etravirine
- —Not posted · NCT00255099
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Emtricitabine/tenofovir disoproxil fumarate: 6 of 6 rows · Etravirine: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Emtricitabine/tenofovir disoproxil fumarate Rows use multiple source trials | Etravirine Rows use multiple source trials |
|---|---|---|
| CD4 absolute change · count Maintenance | 189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.a,b,c NCT00369941 · Phase 3 · registry result, not featured evidence | 205.11 vs 221.39 Efavirenz count @ 48wka,b,c NCT00903682 · Phase 2 · registry result, not featured evidence |
| HIV-1 RNA Less Than 400 Copies Per event count · % of participants Maintenance | 86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk*400 mg b.i.d.d,a,b,c NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 241 Participants as posted show 1 more dose90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 252 Participants as posted | 75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk*d,a,b,c NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted show 1 more dose81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk* NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted |
| Dropout rate | 24.7%e NCT00458393 · Phase 3 show 15 more results16%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 24%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination 0%200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 24.2%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 79.9% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 25% NCT01195467 · Phase 3 · registry result, not featured evidence 19.5% NCT00625404 · Phase 3 · registry result, not featured evidence 25.5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 8.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | n/a: no completion milestonee NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results20.3%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 36%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 40%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 24.8% NCT00665847 · Phase 2 · registry result, not featured evidence 20.3% NCT00903682 · Phase 2 · registry result, not featured evidence 34.1% NCT00128830 · Phase 2 · registry result, not featured evidence 5%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | —e NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 8%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence — NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 1.6%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 7.4% NCT01108510 · Phase 3 · registry result, not featured evidence · combination — NCT01195467 · Phase 3 · registry result, not featured evidence — NCT00625404 · Phase 3 · registry result, not featured evidence 5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence —NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence —NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | 6.7%e NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results3.8%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 4%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 8%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 7.9% NCT00665847 · Phase 2 · registry result, not featured evidence 7.6% NCT00903682 · Phase 2 · registry result, not featured evidence 4.7% NCT00128830 · Phase 2 · registry result, not featured evidence —Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence —Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence — NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 7.5%e NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 0%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence 7.7% NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence 0%Truvada NCT00960622 · Phase 4 · registry result, not featured evidence 9.7% NCT00323492 · Phase 4 · registry result, not featured evidence 11.7%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 18.6% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 10% NCT01195467 · Phase 3 · registry result, not featured evidence 3.2% NCT00625404 · Phase 3 · registry result, not featured evidence 20.3%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 10.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | 10%e NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results15.2%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 8%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 16%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 5% NCT00665847 · Phase 2 · registry result, not featured evidence 13.9% NCT00903682 · Phase 2 · registry result, not featured evidence 21.8% NCT00128830 · Phase 2 · registry result, not featured evidence 25%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 50%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence 0%200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0%200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination 20% NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | e pharyngitis 20.2% (placebo 22.9%) parasitic infection intestinal 18.8% (placebo 17.6%) alanine aminotransferase increased 12.3% (placebo 12.6%) NCT00458393 · Phase 3 show 13 more resultserectile dysfunction 4.8% gastroenteritis 4.8% headache 4.8% NCT02401230 · Phase 4 · registry result, not featured evidence · combination gastroenteritis 5.3% pulmonary embolism 5.3% anxiety 0% NCT02401230 · Phase 4 · registry result, not featured evidence neutrophil count decreased 38% blood albumin decreased 35.6% blood sodium decreased 34% NCT01380080 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 9% diarrhea 8.4% cough 5.2% NCT00724711 · Phase 4 · registry result, not featured evidence · combination diarrhoea 9.7% abdominal pain 4.2% bronchitis 4.2% NCT00323492 · Phase 4 · registry result, not featured evidence 100 mg diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · registry result, not featured evidence 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination diarrhoea 22.1% jaundice 22.1% ocular icterus 20.1% NCT01108510 · Phase 3 · registry result, not featured evidence · combination bilateral arm pain 2.5% cellulitis 2.5% diarrhoea 2.5% NCT01195467 · Phase 3 · registry result, not featured evidence blood phosphorus decreased 19.4% (placebo 18.3%) aspartate aminotransferase increased 13.1% (placebo 11.5%) headache 13.1% (placebo 14.3%) NCT00625404 · Phase 3 · registry result, not featured evidence 400 mg b.i.d. nasopharyngitis 26.7% headache 26% diarrhoea 25.6% NCT00369941 · Phase 3 · registry result, not featured evidence cough 23.1% neutrophil count decreased 23.1% rash 23.1% NCT00089505 · Phase 3 · registry result, not featured evidence neutrophil count decreased 27.3% rash 26.5% cough 24.1% NCT00089505 · Phase 3 · registry result, not featured evidence | e cough 2.8% upper respiratory tract infection 2.8% pregnancy 2.2% NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results400 mg once daily elevated level of transaminase 11.4% hyperbilirubinemia 7.6% hyperlipidemia 7.6% NCT00959894 · Phase 2 · registry result, not featured evidence 400/100 mg cough 16% headache 12% influenza 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination 300/100 mg cough 20% nausea 16% blood bilirubin increased 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 26.7% diarrhoea 15.8% cough 12.9% NCT00665847 · Phase 2 · registry result, not featured evidence nasopharyngitis 21.5% headache 16.5% diarrhoea 10.1% NCT00903682 · Phase 2 · registry result, not featured evidence diarrhoea 17.5% upper respiratory tract infection 17.1% sinusitis 11.4% NCT00128830 · Phase 2 · registry result, not featured evidence blood bicarbonate decreased 90% blood sodium decreased 70% nasal congestion 70% NCT01504841 · Phase 1/2 · registry result, not featured evidence cough 100% nasal congestion 100% rhinorrhoea 100% NCT01504841 · Phase 1/2 · registry result, not featured evidence 200 mg + 200 mg headache 18.8% toothache 12.5% diarrhoea 6.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination 200 mg + 600/100 mg + 200 mg rash maculo-papular 20% scleral hyperaemia 20% headache 13.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination headache 14.3% constipation 10.7% diarrhea 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence breast tenderness 66.7% diarrhea 11.1% headache 11.1% NCT01625169 · Phase na · registry result, not featured evidence · combination altered taste 64% headache 16% rash 16% NCT01427504 · Phase na · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Emtricitabine/tenofovir disoproxil fumarate
show 1 more result
show 3 more results
show 3 more results
show 13 more results
show 1 more result
+ 11 further endpoints in the CSV export.
Etravirine
show 2 more results
show 2 more results
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Etravirine's landscape